GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks

·1 min read
  • GSK plc (NYSE: GSK) and Scynexis Inc (NASDAQ: SCYX) have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets).

  • The FDA approved the antifungal for vulvovaginal candidiasis (VVC) and reduced the incidence of recurrent VVC (RVVC).

  • This exclusive agreement gives GSK rights to commercialize Brexafemme for VVC and RVVC while continuing to develop ibrexafungerp, which is in phase 3 trials for potentially treating invasive candidiasis (IC), which affects the blood or internal organs.

  • Scynexis has been looking for a partner after it said last October that it was winding down promotional activities for the drug and announced workforce reduction.

  • Infectious diseases and HIV represent around two-thirds of GSK's pipeline. Brexafemme complements GSK's pipeline alongside late-stage antibiotics gepotidacin and tebipenem.

  • GSK will make an upfront payment to Scynexis of $90 million.

  • Scynexis is due to get $245.5 million in development, regulatory and commercial milestones there — with a separate $15 million tied to an FDA approval. Sales-related milestones add up to another $242.5 million.

  • Price Action: SCYX shares are up 64.70% at $2.75 on the last check Thursday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks originally appeared on


© 2023 Benzinga does not provide investment advice. All rights reserved.